الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 140 |  |  |
| | | from | 140 | | |
Abstract
P
soriasis is a common and chronic inflammatory skin disease whose exact pathogenesis remains uncertain. Nowadays, research focuses not only on understanding the genesis of skin lesions but especially on the explanation of systemic disorders associated with psoriasis.
Elevated risk of the occurrence of chronic inflammatory diseases in psoriatic patients, such as IBD, NAFLD, DM, obesity, or MS has been proven in various studies.
Understanding the connection between the inflammatory state, psoriasis progression and severity, as well as the cardiometabolic dysfunction leads to more research for new markers of inflammation that would provide a tool for early diagnosis and discovery of new therapeutic methods for the systemic complications.
Currently the use of fibroblast growth factor, namely (FGF21), is considered a promising approach to assess the risk and diagnose the presence of psoriasis-related cardiometabolic abnormalities.
The aim of the present work is to evaluate the serum level of FGF21 in psoriatic patients versus healthy controls and to correlate it with the disease severity (PASI Score), BMI, metabolic parameters. We included 30 patients with plaque psoriasis and 30 matched age, sex and BMI apparent healthy controls.
Measurement of serum FGF-21 in both groups revealed that serum FGF-21 before and after treatment were significantly higher in psoriatic patients compared to control subjects. Also, there was a highly statistical significant positive correlation between FGF-21 levels and PASI score.
Serum FGF-21 levels in psoriatic patients were significantly lower after treatment compared to before treatment.
In conclusion, our study revealed that FGF-21 can be used as indicator for psoriasis severity. However, there was no correlation between FGF-21 and metabolic parameters as well as blood pressure which are known risk factors for the development of cardiovascular diseases